News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antibiotics Maker Steri-Pharma Wants to Create 72 New Jobs in New York



4/19/2017 6:01:48 AM

Antibiotics Maker Steri-Pharma Wants to Create 72 New Jobs in New York April 19, 2017
By Alex Keown, BioSpace.com Breaking News Staff

SYRACUSE, N.Y. – Steri-Pharma, the maker of antibiotics, hopes to secure about $1 million in tax breaks to allow the company to undertake a $50 million expansion of its operations in Syracuse, N.Y. and create 72 full-time jobs.


The company currently operates a 73,882 square-foot facility in Syracuse and the company is looking to add an extra 18,000 square-feet of space to the facility. The Post Standard of Syracuse reported the expansion will include two clean rooms, sterile production and filling rooms and warehouse space. In addition to interior expansion, the company said it intends to make some site improvements including repairs to a retaining wall on a nearby creek, utility work and construction of a covered walkway that will connect the current building to the new addition. Steri-Pharma plans to begin construction in May and the projects are expected to be concluded in July 2018, the company said, according to the Post.

With the additional space, Steri-Pharma said it will be able to expand employment from 48 to 120 employees, although information about the types of positions that will be added were not reported. The company said the expansion of employment will allow the company to triple production and address capacity constraints that the current line will realize in the near future,” the Post Standard reported.
  Related Jobs  
  Clinical Operations Lead – Astra
  Senior Scientist, Cell Biology - AnaptysBio
  Research Associate II - Seattle Genetics
  Scientist I/II - MedImmune
  Clinical Trial Manager - Celgene
  Local Study Leader - Astra
  View More Jobs


Steri-Pharma has been using the Syracuse manufacturing site since 2010 after acquiring the facility from Hanford Pharmaceuticals, according to the Post Standard. Steri-Pharma is seeking a 15-year payment-in-lieu-of-tax agreement that would provide the company will a full exemption from property taxes for 10 years and then declining partial exemptions for an additional five years, according to the report.

Steri-Pharma, which has its corporate offices in Paramus, N.J., manufactures parenteral cephalosporin pharmaceutical products; non-sterile, intramamary infusion products and veterinary products for U.S. and international markets, according to the company website. Steri-Pharma is the maker of an antibiotic approved by the U.S. Food and Drug Administration in 2012 through a law that “provides incentives to companies to develop antibiotics that are effective against drug-resistant bacteria.”

Parts of New York are seeing a surge of investments by pharmaceutical companies, particularly in the Westchester County area. Earlier this year, officials approved the first steps for a $1.2 billion biotech development, the Westchester Bioscience and Technology Center. When the site is fully developed, it will include 2,252,600 square feet of biotech and research space, as well as 400,000 square feet of medical offices.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES